Gemifloxacin Mesylate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317968

CAS#: 210353-53-0 (mesylate)

Description: Gemifloxacin is an oral broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. Vansen Pharma Inc. has licensed the active ingredient from LG Life Sciences of Korea. Gemifloxacin has been shown to be active against most strains of the aerobic gram-positive microorganisms- Streptococcus pneumoniae- including multi-drug resistant Streptococcus pneumoniae. Gemifloxacin is a third generation antibacterial quinolone agent that is also fluorinated.

Chemical Structure

img
Gemifloxacin Mesylate
CAS# 210353-53-0 (mesylate)
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 317968
Name: Gemifloxacin Mesylate
CAS#: 210353-53-0 (mesylate)
Chemical Formula: C19H24FN5O7S
Exact Mass: 0.00
Molecular Weight: 485.487
Elemental Analysis: C, 47.01; H, 4.98; F, 3.91; N, 14.43; O, 23.07; S, 6.60

Price and Availability

Size Price Availability Quantity
50mg USD 110 Ready to ship
200mg USD 350 2 Weeks
500mg USD 650
1g USD 1150 2 Weeks
2g USD 1950 2 Weeks
Bulk inquiry

Related CAS #: 175463-14-6 (free base)   210353-53-0 (mesylate),  

Synonym: Gemifloxacin Mesylate; Factive; LB-20304a; SB-265805-S; LB 20304; LB-20304; LB20304; SB 265805; SB-265805;

IUPAC/Chemical Name: 7-[(4Z)-3-(aminomethyl)-4-methoxyiminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid;methanesulfonic acid

InChi Key: JIYMVSQRGZEYAX-CWUUNJJBSA-N

InChi Code: InChI=1S/C18H20FN5O4.CH4O3S/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17;1-5(2,3)4/h4,7,9-10H,2-3,5-6,8,20H2,1H3,(H,26,27);1H3,(H,2,3,4)/b22-14+;

SMILES Code: CO/N=C/1\CN(CC1CN)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F.CS(=O)(=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Product Data
Certificate of Analysis:
View CoA: current batch, Lot#A21K03S22
Safety Data Sheet (SDS):
View Safety Data Sheet (SDS)
Instruction:
View handling instruction
Biological target: Gemifloxacin mesylate is an oral broad-spectrum quinolone antibacterial agent, used in the treatment of acute bacterial exacerbation of chronic bronchitis, and mild-to-moderate pneumonia.
In vitro activity: As shown in Figure 1(a), GMF (gemifloxacin) did not affect the viability of SW620 and LoVo cells at concentrations ranging from 1 to 20 μg/mL. However, GMF exhibited an inhibitory effect on the migration of SW620 and LoVo cells, as determined by wound-healing assay (Figure 1(b)). In addition, quantitative transwell analysis also revealed that GMF decreased the migration of SW620 and LoVo cells in a dose-dependent manner (Figure 1(c)). Next, this study assessed the effect of GMF on the invasive ability of colon cancer cells. Compared to vehicle-treated cells, GMF treatment attenuated SW620 and LoVo cell invasion in a dose-dependent manner after treatment for 48 hours (Figure 1(d)). Reference: Biomed Res Int. 2013;2013:159786. https://pubmed.ncbi.nlm.nih.gov/24386633/
In vivo activity: Negative control group is represented by 1, gemifloxacin treatment 25 mg/kg is represented by 2, gemifloxacin treatment 50 mg/kg is represented by 3 while gemifloxacin treatment 75 mg/kg is represented by 4. Significant (***P<0.001) decrease in leukocyte count is found in group 2 and group 3 while significant (**P<0.01) decrease is observed in gemifloxacin treatment 75 mg/kg. Significant (P<0.05) decrease in leukocyte mean value is observed in mouse treatment group 3 and 4 before cyclophosphamide administration. Reference: Iran J Basic Med Sci. 2016 Sep;19(9):985-992. https://pubmed.ncbi.nlm.nih.gov/27803786/

Preparing Stock Solutions

The following data is based on the product molecular weight 485.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Kan JY, Hsu YL, Chen YH, Chen TC, Wang JY, Kuo PL. Gemifloxacin, a fluoroquinolone antimicrobial drug, inhibits migration and invasion of human colon cancer cells. Biomed Res Int. 2013;2013:159786. doi: 10.1155/2013/159786. Epub 2013 Dec 10. PMID: 24386633; PMCID: PMC3872387. 2. Araujo F, Slifer T, Li S, Kuver A, Fong L, Remington J. Gemifloxacin inhibits cytokine secretion by lipopolysaccharide stimulated human monocytes at the post-transcriptional level. Clin Microbiol Infect. 2004 Mar;10(3):213-9. doi: 10.1111/j.1198-743x.2004.00824.x. PMID: 15008941. 3. Umair M, Javeed A, Ghafoor A, Ashraf M. Immunomodulatory activities of gemifloxacin in mice. Iran J Basic Med Sci. 2016 Sep;19(9):985-992. PMID: 27803786; PMCID: PMC5080429. 4. Azoulay-Dupuis E, Bédos JP, Mohler J, Moine P, Cherbuliez C, Peytavin G, Fantin B, Köhler T. Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model. Antimicrob Agents Chemother. 2005 Mar;49(3):1046-54. doi: 10.1128/AAC.49.3.1046-1054.2005. PMID: 15728901; PMCID: PMC549237.
In vitro protocol: 1. Kan JY, Hsu YL, Chen YH, Chen TC, Wang JY, Kuo PL. Gemifloxacin, a fluoroquinolone antimicrobial drug, inhibits migration and invasion of human colon cancer cells. Biomed Res Int. 2013;2013:159786. doi: 10.1155/2013/159786. Epub 2013 Dec 10. PMID: 24386633; PMCID: PMC3872387. 2. Araujo F, Slifer T, Li S, Kuver A, Fong L, Remington J. Gemifloxacin inhibits cytokine secretion by lipopolysaccharide stimulated human monocytes at the post-transcriptional level. Clin Microbiol Infect. 2004 Mar;10(3):213-9. doi: 10.1111/j.1198-743x.2004.00824.x. PMID: 15008941.
In vivo protocol: 1. Umair M, Javeed A, Ghafoor A, Ashraf M. Immunomodulatory activities of gemifloxacin in mice. Iran J Basic Med Sci. 2016 Sep;19(9):985-992. PMID: 27803786; PMCID: PMC5080429. 2. Azoulay-Dupuis E, Bédos JP, Mohler J, Moine P, Cherbuliez C, Peytavin G, Fantin B, Köhler T. Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model. Antimicrob Agents Chemother. 2005 Mar;49(3):1046-54. doi: 10.1128/AAC.49.3.1046-1054.2005. PMID: 15728901; PMCID: PMC549237.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Foroughipour M, Nezamzadeh-Ejhieh A. CaTiO3/g-C3N4 heterojunction-based composite photocatalyst: Part I: Experimental design, kinetics, and scavenging agents' effects in photocatalytic degradation of gemifloxacin. Chemosphere. 2023 May 24;334:139019. doi: 10.1016/j.chemosphere.2023.139019. Epub ahead of print. PMID: 37236274.


2: Ullah A, Ahmad S, Ali N, Hussain H, Allahyani M, Almehmadi M, Alsaiari AA, Abdulaziz O, Almarshad F, Bukhari SH. The Effects of Moxifloxacin and Gemifloxacin on the ECG Morphology in Healthy Volunteers: A Phase 1 Randomized Clinical Trial. Diagnostics (Basel). 2023 Mar 24;13(7):1234. doi: 10.3390/diagnostics13071234. PMID: 37046452; PMCID: PMC10092949.


3: Faisal M, Ahmed J, Jalalah M, Alsareii SA, Alsaiari M, Harraz FA. Rapid elimination of antibiotic gemifloxacin mesylate and methylene blue over Pt nanoparticles dispersed chitosan/g-C3N4 ternary visible light photocatalyst. Environ Sci Pollut Res Int. 2023 May;30(22):61710-61725. doi: 10.1007/s11356-023-26456-w. Epub 2023 Mar 18. PMID: 36933133.


4: Kalaria VJ, Saisivam S, Alshishani A, Aljariri Alhesan JS, Chakraborty S, Rahamathulla M. Design and evaluation of in situ gel eye drops containing nanoparticles of Gemifloxacin Mesylate. Drug Deliv. 2023 Dec;30(1):2185180. doi: 10.1080/10717544.2023.2185180. PMID: 36876464; PMCID: PMC10191058.


5: Jang MG, Cha S, Kim S, Lee S, Lee KE, Shin KH. Application of tree-based machine learning classification methods to detect signals of fluoroquinolones using the Korea Adverse Event Reporting System (KAERS) database. Expert Opin Drug Saf. 2023 Feb 23:1-8. doi: 10.1080/14740338.2023.2181341. Epub ahead of print. PMID: 36794497.


6: Singh V, Dhankhar P, Dalal V, Tomar S, Golemi-Kotra D, Kumar P. Drug- Repurposing Approach To Combat Staphylococcus aureus: Biomolecular and Binding Interaction Study. ACS Omega. 2022 Oct 18;7(43):38448-38458. doi: 10.1021/acsomega.2c03671. PMID: 36340146; PMCID: PMC9631409.


7: Wang J, Gagne JJ, Kattinakere-Sreedhara S, Fischer MA, Bykov K. Association between initiation of fluoroquinolones and hospital admission or emergency department visit for suicidality: population based cohort study. BMJ. 2022 Oct 4;379:e069931. doi: 10.1136/bmj-2021-069931. PMID: 36195324; PMCID: PMC9530980.


8: Shamim S, Gul S, Rauf A, Rashid U, Khan A, Amin R, Akhtar F. Gemifloxacin- transition metal complexes as therapeutic candidates: antimicrobial, antifungal, anti-enzymatic, and docking studies of newly synthesized complexes. Heliyon. 2022 Aug 22;8(8):e10378. doi: 10.1016/j.heliyon.2022.e10378. PMID: 36061017; PMCID: PMC9433694.


9: Rezayaraghi F, Jafari-Nodoushan H, Mojtabavi S, Golshani S, Jahandar H, Faramarzi MA. Hybridization of laccase with dendrimer-grafted silica-coated hercynite-copper phosphate magnetic hybrid nanoflowers and its application in bioremoval of gemifloxacin. Environ Sci Pollut Res Int. 2022 Dec;29(59):89255-89272. doi: 10.1007/s11356-022-21959-4. Epub 2022 Jul 18. PMID: 35843973.


10: Vuppala S, Kim J, Joo BS, Choi JM, Jang J. A Combination of Pharmacophore- Based Virtual Screening, Structure-Based Lead Optimization, and DFT Study for the Identification of S. epidermidis TcaR Inhibitors. Pharmaceuticals (Basel). 2022 May 21;15(5):635. doi: 10.3390/ph15050635. PMID: 35631461; PMCID: PMC9146354.


11: Elshafie HS, Sadeek SA, Camele I, Mohamed AA. Biochemical Characterization of New Gemifloxacin Schiff Base (GMFX-o-phdn) Metal Complexes and Evaluation of Their Antimicrobial Activity against Some Phyto- or Human Pathogens. Int J Mol Sci. 2022 Feb 14;23(4):2110. doi: 10.3390/ijms23042110. PMID: 35216223; PMCID: PMC8877648.


12: Ullah A, Ahmad S, Ali N, Rahman SU, Hussain H, Alghamdi S, Almehmadi M, Dablool AS, Bannunah AM, Bukhari SH, Almarshad F. Insulinotropic Potential of Moxifloxacin and Gemifloxacin: An In Vivo Rabbits Model Study Followed by Randomized Phase I Clinical Trial. Antibiotics (Basel). 2022 Jan 24;11(2):148. doi: 10.3390/antibiotics11020148. PMID: 35203750; PMCID: PMC8868483.


13: Reinecke R, Nazir TA, Carvallo S, Jayez J. Factives at hand: When presupposition mode affects motor response. J Exp Psychol Gen. 2022 Sep;151(9):2173-2194. doi: 10.1037/xge0001167. Epub 2022 Feb 14. PMID: 35157482.


14: Wang Z, Zhang J, Liu S, Zhang Y, Chen C, Xu M, Zhu Y, Chen B, Zhou W, Cui S, Yang B, Chen J. Prevalence, antimicrobial resistance, and genotype diversity of Salmonella isolates recovered from retail meat in Hebei Province, China. Int J Food Microbiol. 2022 Mar 2;364:109515. doi: 10.1016/j.ijfoodmicro.2021.109515. Epub 2021 Dec 29. PMID: 35030440.


15: Hassan HAFM, Ali AI, ElDesawy EM, ElShafeey AH. Pharmacokinetic and Pharmacodynamic Evaluation of Gemifloxacin Chitosan Nanoparticles As an Antibacterial Ocular Dosage Form. J Pharm Sci. 2022 May;111(5):1497-1508. doi: 10.1016/j.xphs.2021.12.016. Epub 2021 Dec 17. PMID: 34929155.


16: Abidullah -, Ahmad S, Ali N, Almarshad F, Nabi M, Rahman SU, Ullah S, Khan J, Hussain H, Bukhari SH. Moxifloxacin and gemifloxacin mediates its antispasmodic profile via ATP-sensitive potassium channels: An in-vitro bioassay study. Pak J Pharm Sci. 2021 Sep;34(5(Supplementary)):1983-1988. PMID: 34836870.


17: Ahmad T, Mahbood F, Sarwar R, Iqbal A, Khan M, Muhammad S, Al-Riyami K, Hussain N, Uddin J, Khan A, Al-Harrasi A. Synthesis of gemifloxacin conjugated silver nanoparticles, their amplified bacterial efficacy against human pathogen and their morphological study via TEM analysis. Artif Cells Nanomed Biotechnol. 2021 Dec;49(1):661-671. doi: 10.1080/21691401.2021.2003805. PMID: 34818127.


18: Kumar Das K, Sahoo DP, Mansingh S, Parida K. ZnFe2O4@WO3-X /Polypyrrole: An Efficient Ternary Photocatalytic System for Energy and Environmental Application. ACS Omega. 2021 Nov 1;6(45):30401-30418. doi: 10.1021/acsomega.1c03705. PMID: 34805671; PMCID: PMC8600529.


19: Mohamed AA, Elshafie HS, Sadeek SA, Camele I. Biochemical Characterization, Phytotoxic Effect and Antimicrobial Activity against Some Phytopathogens of New Gemifloxacin Schiff Base Metal Complexes. Chem Biodivers. 2021 Sep;18(9):e2100365. doi: 10.1002/cbdv.202100365. Epub 2021 Jul 20. PMID: 34288421.


20: Ma Q, Cong W, Liu Y, Geng Z, Lin Y, Wang Z. Experimental and computational study on the enantioseparation of four chiral fluoroquinolones by capillary electrophoresis with sulfated-β-cyclodextrin as chiral selector. Chirality. 2021 Sep;33(9):549-557. doi: 10.1002/chir.23340. Epub 2021 Jul 18. PMID: 34275169.